India GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity), By Route of Administration (Parenteral, Oral), By Product, By Distribution Channel, And Segment Forecasts, 2025 - 2030

India GLP-1 Receptor Agonist Market Trends

The India GLP-1 receptor agonist market size was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030. The market is driven by the rising incidence of chronic conditions such as type 2 diabetes and obesity, increasing R&D activities for novel therapeutics, patent expiry, and the entry of generic alternatives. According to the International Diabetes Federation report of 2024, 8.98 million adults are prone to diabetes, and approximately 185 million people will succumb to diabetes by 2050 in India.

India has witnessed a significant rise in metabolic disorders due to rapid urbanization, sedentary lifestyles, and poor dietary habits. With rising obesity rates, the demand for effective treatments is continuously increasing. GLP-1 receptor agonists are recognized as a promising therapeutic class for managing both obesity and type 2 diabetes by improving insulin sensitivity and promoting weight loss. These drugs have gained popularity due to their proven efficacy, making them a sought-after treatment for millions suffering from these chronic conditions in India.

The Ministry of Ayush, India, has implemented various initiatives to combat obesity and promote weight management through Ayurveda. The All India Institute of Ayurveda (AIIA) in New Delhi offers specialized treatments such as Panchakarma, Ayurvedic medicines, dietary guidelines, and practicing yoga. The Central Council for Research in Ayurvedic Sciences (CCRAS) is primarily involved in formulating, developing, and promoting Ayurvedic medicines. CCRAS conducts clinical trials to evaluate the safety and efficacy of Ayurvedic formulations and practices in managing lifestyle-related disorders such as diabetes, hypertension, obesity, and stress-related ailments.

The Ayurswasthya Yojana supports community-based healthcare initiatives to address obesity and related lifestyle disorders. Through strategic collaboration with the Council of Scientific and Industrial Research (CSIR), the program integrates traditional Ayurvedic knowledge with modern scientific approaches, thereby advancing research and improving the prevention and management of these conditions.

Pipeline Analysis

The table below illustrates pipeline products involving GLP-1 receptor agonist, for type-2 Diabetes Mellitus and obesity. These trials of GLP-1 receptor agonists reveal a promising future. Moreover, research and clinical usage are expanding into other potential indications, including cardiovascular risk and PCOS. Several pharmaceutical companies are actively developing new and enhanced GLP-1 therapies with improved efficacy, safety profiles, and patient convenience. In addition to the existing GLP-1 drugs such as Semaglutide and Liraglutide, several next-generation agents are in various stages of clinical trials. Tirzepatide, a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is showing promising results in clinical trials for weight loss and diabetes management. These advancements suggest a dynamic pipeline, potentially significantly transforming the landscape of obesity and diabetes treatment in the coming years.

Patent Expiry and Biosimilar of GLP-1 Receptor Agonists

The patent expiry of GLP-1 receptor agonists in India is set to significantly impact the market for these medications, particularly for diabetes and obesity treatments. Initially developed by Novo Nordisk, Liraglutide had its patent expire globally in 2023. Indian pharmaceutical companies such as Cadila Healthcare (Zydus) are working on biosimilar versions to offer more affordable alternatives. Semaglutide, another popular GLP-1 receptor agonist, is expected to expire its patent in 2026. It will also open doors for generic versions and biosimilars, by companies such as Mylan, looking to introduce cost-effective options. The expiration of patents for these drugs is expected to increase market competition, which may lead to reduced treatment costs and enhanced accessibility for Indian patients, particularly in a price-sensitive healthcare landscape The following table outlies the patent expiry and biosimilar status of GLP-1 receptor agonists from Indian pharmaceutical companies, outlining their market dynamics in India.

Opportunities for GLP-1 Receptor Agonists Beyond Diabetes and Obesity

GLP-1 receptor agonists present significant opportunities beyond diabetes and obesity, with potential applications in chronic diseases. These emerging indications offer high unmet medical needs and commercial potential, encouraging manufacturers to explore innovative therapeutic areas.

Industry Characteristics

The degree of innovation in the India GLP-1 receptor agonist industry is significant, with ongoing advancements in drug formulations and delivery methods. Innovations such as oral GLP-1 receptor agonists, longer-acting injectable formulations, and combination therapies increase patient compliance and improve treatment outcomes. Companies are also working on more affordable biosimilars to offer cost-effective alternatives to patented drugs. These innovations not only enhance the efficacy of diabetes and obesity treatments but also expand market access, ensuring better healthcare solutions for a growing patient population in India.

Entering the Indian biopharmaceutical market presents notable challenges. Established players such as Novo Nordisk and Biocon's dominancecreate a highly competitive environment with significant brand loyalty and market penetration. In addition, pricing remains a critical factor in this cost-sensitive market, necessitating the development of affordable and value-driven solutions. Navigating the regulatory landscape also poses hurdles, as obtaining approvals from the Central Drugs Standard Control Organization (CDSCO) can be time-consuming and complex for new entrants.

Regulations significantly impact the India GLP-1 receptor agonist market, particularly in drug approval, pricing, and distribution. The Central Drugs Standard Control Organization (CDSCO) plays a key role in ensuring drug safety and efficacy, with a focus on clinical trial data and product labeling. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of drugs to ensure affordability for Indian patients. These regulations ensure that only safe, effective, and affordable GLP-1 receptor agonists reach the market, but they can also delay market entry and limit pricing flexibility.

The India GLP-1 receptor agonist industry faces competition from several product substitutes, such as other diabetes drugs like SGLT-2 inhibitors, DPP-4 inhibitors, and insulin. Although these alternatives may not offer the same degree of weight-loss efficacy as GLP-1 receptor agonists, they are generally cost-effective and have a well-established safety and usage profile. Furthermore, non-pharmacological treatments such as lifestyle changes, including diet and exercise, are usually recommended as substitutes for managing type 2 diabetes and obesity, further increasing competition for GLP-1 receptor agonists in the Indian market.

The end-user concentration in the India GLP-1 receptor agonist industry primarily focuses on individuals with type 2 diabetes and obesity. This market is highly concentrated among patients who have struggled with managing their condition using oral medications alone and are seeking more effective treatments. Hospitals, specialty clinics, and endocrinologists’ offices are key distribution points for these drugs, with a growing emphasis on patients with severe or uncontrolled diabetes. Moreover, the demand from private healthcare settings is increasing as these drugs become more widely recognized for their efficacy in managing metabolic disorders.

Application Insights

Type 2 Diabetes Mellitus (T2DM) is the largest application area in the Indian market, accounting for 71.9% in 2024, driven by the country’s high diabetes prevalence, affecting over 77 million adults. GLP-1 receptor agonists like semaglutide, liraglutide, and dulaglutide are widely adopted for their effectiveness in lowering blood glucose, promoting weight loss, and reducing cardiovascular risks. The robust clinical benefits and growing physician adoption are key drivers supporting sustained market growth. In addition, upcoming patent expirations, especially for semaglutide, are expected to boost affordability and accessibility, further solidifying T2DM as the primary driver of GLP-1 receptor agonist use in India.

Obesity is emerging as the fastest-growing segment, driven by the country's escalating obesity rates and increasing awareness of weight management. The recent launch of Eli Lilly's Mounjaro has further accelerated this growth, with usage tripling within a month of its introduction. Furthermore, the anticipated patent expirations for semaglutide in 2026 are expected to pave the way for more affordable generic options, enhancing accessibility and fueling market expansion.

Product Insights

Trulicity (dulaglutide) held a significant market share of 78.44% in 2024, among GLP-1 receptor agonists, primarily due to its once-a-week administration and robust efficacy in managing type 2 diabetes. It is an injection developed by Eli Lilly, indicated for use in adults and children aged 10 years and older. Eli Lilly's strategic partnership with Cipla has enhanced accessibility, ensuring broader distribution nationwide. This collaboration leverages Cipla's extensive local presence to reach India's vast diabetic population, which is estimated to be over 70 million adults. While other GLP-1 receptor agonists such as semaglutide are anticipated to enter the market post-2026 patent expiry, Trulicity's established presence and distribution network position it as a leading choice in diabetes management in India.

Other segment including products such as SOLIQUA (lixisenatide) and Bydureon, are the fastest growing ones during the forecast period. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the therapeutic landscape for type 2 diabetes and obesity, offering robust glycemic control, clinically meaningful weight loss, and cardiovascular protective benefits. Beyond popular GLP-1 receptor agonists like Ozempic and Trulicity, several other agents contribute significantly to diabetes and obesity management. Early GLP-1 receptor agonists such as Byetta and Bydureon offer short- and long-acting exenatide formulations. Lixisenatide provides once-a-day dosing with distinct clinical advantages, while efpeglenatide represents a newer long-acting therapeutic option in this class.. Emerging oral agents such as danuglipron are enhancing patient convenience and adherence. Dual agonists like cotadutide, which target multiple receptors, offer the potential for improved therapeutic outcomes. Meanwhile, biosimilars are playing a crucial role in expanding access, particularly in price-sensitive markets like India. These diverse therapies underscore the dynamic evolution and developing potential of GLP-1 receptor agonists beyond the established leading brands.

Route of Administration Insights

The parenteral (injectable) segment holds the largest market share, driven by India's proven efficacy and rapid onset of action of injectable formulations. Advancements also influence the preference for injectable formulationsin drug delivery systems, including auto-injectors, which enhance patient convenience and adherence. This dominance is attributed to the availability of well-established injectable GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), which offer high bioavailability and consistent therapeutic outcomes.

The oral GLP-1 receptor agonist segment is experiencing rapid growth within India's diabetes and obesity treatment landscape. Novo Nordisk's oral semaglutide tablet, Rybelsus, significantly contributed to market growth. Key contributors to this expansion include introducing innovative medications such as semaglutide-based drugs like Rybelsus and the launch of Mounjaro (tirzepatide), which have gained popularity for their effectiveness in weight management. The market's growth is also supported by improved affordability and accessibility of these treatments, reflecting a broader trend towards proactive health management in the country.

Distribution Channel Insights

Retail pharmacies represent the largest distribution channel in the market, accounting for over 55.39% share in 2024. This dominance is attributed to their widespread accessibility, extended operating hours, and the convenience offered to patients seeking outpatient care for Type 2 diabetes and obesity. Retail pharmacies are increasingly integrating services like patient education, home delivery, and teleconsultations, further enhancing their offerings. The anticipated patent expirations for semaglutide in 2026 are expected to introduce more affordable generic options, potentially expanding the reach of GLP-1 therapies through retail channels.

Online pharmacies are rapidly emerging as the fastest-growing distribution channel in this market. This growth is driven by the increasing adoption of digital health solutions, e-commerce, and telemedicine services, making it convenient for patients to access medications from the comfort of their homes. Online platforms offer advantages such as competitive pricing, doorstep delivery, and a wide range of product options, appealing to a broad consumer base. The rise of online pharmacies is particularly beneficial for patients in remote areas or those with mobility issues, enhancing medication adherence and overall treatment outcomes..

Country Insights

India GLP-1 Receptor Agonist Market Trends

The GLP-1 receptor agonists market in India is witnessing robust growth, driven by the rising prevalence of type 2 diabetes and obesity. Key growth factors include increasing awareness of comprehensive diabetes management and a growing demand for effective weight-loss therapies. Indian pharmaceutical companies such as Biocon, Dr. Reddy's Laboratories, and Cipla are pivotal in developing cost-effective generics and biosimilars. Innovations, including oral formulations and combination therapies, further enhance the spectrum of treatment options. As key patents expire, the market landscape is becoming more dynamic, providing access to GLP-1 therapies for a wider patient population in India.

Key India GLP-1 Receptor Agonist Company Insights

The Indian market is dominated by major players such as Biocon, Dr. Reddy's Laboratories, and Novo Nordisk A/S. These players leverage strong brand recognition, regulatory approvals, and established distribution networks. Pricing strategies, supply chain effectiveness, and product differentiation shape competitive dynamics in this market. Manufacturers, particularly in the Asia-Pacific region, are also expanding with cost-effective formulations. As healthcare systems focus on providing affordable diabetes treatments, market competition is anticipated to intensify. Overall, the market is expected to experience significant growth during the forecast period.

Recent Developments

• In April 2025, Sanofi India introduced its new diabetes medication, Soliqua, following marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua is indicated for the treatment of adults with obesity and type 2 diabetes mellitus, aimed at improving glycemic control when used alongside diet and exercise.

• In April 2025, Novo Nordisk announced that it would launch its blockbuster obesity medication, Wegovy (injectable semaglutide), in India by 2026 to manage diabetes and obesity.

• In March 2025, Eli Lilly announced the launch of Mounjaro (Trizepatide), aglucagon-like peptide (GLP-1) receptor agonist in India. This medicine helps to manage blood sugar levels and control appetite for diabetes and obesity.

India GLP-1 Receptor Agonist Market Report Scope

India GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the India GLP-1 receptor agonist market report based on product, application, route of administration, and distribution channel:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Ozempic (semaglutide)

  • Trulicity

  • Mounjaro (tirzepatide)

  • Wegovy (semaglutide)

  • Rybelsus (oral semaglutide)

  • Saxenda

  • Victoza (liraglutide)

  • Zepbound

  • Other Products (SOLIQUA (lixisenatide), Bydureon)

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Type 2 Diabetes Mellitus

  • Obesity

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Parenteral

  • Oral

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies